MolecularPartners_Logo.jpg
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
October 31, 2024 16:00 ET | Molecular Partners
Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected...
MolecularPartners_Logo.jpg
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
October 25, 2024 01:00 ET | Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
MolecularPartners_Logo.jpg
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
October 22, 2024 01:00 ET | Molecular Partners
Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two programs (previously one each)Molecular Partners will hold...
MolecularPartners_Logo.jpg
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
October 22, 2024 01:00 ET | Molecular Partners
Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high specificity for DLL3 as precision...
MolecularPartners_Logo.jpg
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
October 04, 2024 01:00 ET | Molecular Partners
Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors Biomarker data on completed phase 1 study of MP0317 (FAP x CD40)...
MolecularPartners_Logo.jpg
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
September 27, 2024 01:00 ET | Molecular Partners
First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712 treatment leads to strong tumor growth inhibition with a good safety profile in vivo ...
MolecularPartners_Logo.jpg
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
August 26, 2024 16:00 ET | Molecular Partners
First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025 Strategic collaboration agreement signed with...
MolecularPartners_Logo.jpg
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
June 17, 2024 01:00 ET | Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
MolecularPartners_Logo.jpg
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
June 14, 2024 01:00 ET | Molecular Partners
Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activatorsPreclinical safety, efficacy, and pharmacokinetics support MP0621’s...
MolecularPartners_Logo.jpg
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
June 11, 2024 01:00 ET | Molecular Partners
MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano MedPositive tumor to kidney ratio and biodistribution,...